DISTRIBUTION OF THE MOST COMMON GENETIC VARIANTS ASSOCIATED WITH A VARIABLE DRUG RESPONSE IN THE POPULATION OF THE REPUBLIC OF MACEDONIA
Kapedanovska Nestorovska A1, Jakovski K2, Naumovska Z1, Hiljadnikova Bajro M1, Sterjev Z1, Eftimov A1, Matevska Geskovska N1, Suturkova L1, Dimitrovski K3, Labacevski N3, Dimovski AJ
*Corresponding Author: Aleksandar J. Dimovski, MD., Ph.D., Center for Biomolecular and Pharmaceutical Analysis, Faculty of Pharmacy, University Ss Cyril and Methodius, Mother Theresa 47, Skopje 1000, Republic of Macedonia. Tel: +389-2-3217-580; +389-2-3119-694. Fax: +389-2-3290-830; +389-2-3123 054. E-mail: adimovski@ff.ukim.edu.mk
page: 5

REFERENCES

1. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011; 63(2): 437-459. 2. Foster MW, Sharp RR. Race, ethnicity, and genomics: Social classifications as proxies of biological heterogeneity. Genome Res. 2002; 12(6): 844-850. 3. Stranger BE, Stahl EA, Raj T. Progress and promise of genome-wide association studies for human complex trait genetics. Genetics. 2011; 187(2): 367-383. 4. Li J, Zhang L, Zhou H, Stoneking M, Tang K. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum Mol Genet. 2011; 20(3): 528-540. 5. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scale. Pharmacogenet Genomics. 2009; 19(2): 170-179. 6. Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, et al. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 2010; 20(8): 1020-1036. 7. McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012; 8(3): 371-382. 8. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects. Pharmacogenomics J. 2013; 13(1): 1-11. 9. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009; 41(2): 89-295. 10. Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, et al. The AmpliChip CYP450 test: Cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009; 9(1): 34-41. 11. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007; 17(2): 93-101. 12. Kalow W. Pharmacogenetics: A historical perspective. In: McLeod HL, DeVane CL, Haga SB, Johnson JA, Knoel DL, Kolesar JM, et al., Eds. Pharmacogenomics: Application to Patient Care, 2nd ed. Lenexa, KS: American College of Clinical Pharmacy. 2009: 22-31. 13. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002; 48(10): 1668-1671. 14. Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther. 1999; 66(2): 185-192. 15. Buzková H, Pechandová K, Slanar O, Perlik F. Frequency of single nucleotide polymorphisms of CYP-2D6 in the Czech population. Cell Biochem Funct. 2008; 26(1): 76-81. 16. Qumsieh RY, Ali BR, Abdulrazzaq YM, Osman O, Akawi NA, Bastaki SM. Identification of new alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in Emiratis. PLoS One. 2011; 6(12): e28943. doi: 10.1371/journal.pone.0028943. 17. Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res. 2004; 50(2): 195-200. 18. Bozina N, Granić P, Lalić Z, Tramisak I, Lovrić M, Stavljenić-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J. 2003; 44(4): 425-428. 19. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007; 21(4): 419-426. 20. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of Pglycoprotein in a Russian population. Eur J Clin Pharmacol. 2003; 59(4): 303-312. 21. Yamada H, Dahl ML, Lannfelt L, Viitanen M, Winblad B, Sjoqvist F. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol. 1998; 54(6): 479-481. 22. Falzoi M, Pira L, Lazzari P, Pani L. Analysis of CYP2D6 allele frequencies and identification of novel SNPs and sequence variations in Sardinians. ISRN Genet. 2013; 2013. Article ID 204560; http://dx.doi.org/10.5402/ 2013/204560. 23. Jakovski K, Kapedanovska Nestorovska A, Labacevski N, Dimovski AJ. Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population of R. Macedonia. Pharmazie. 2013; 68(11): 893-898. 24. Kapedanovska Nestorovska A, Cvetkovska Dimitrovska A, Suturkova Lj. Genetic profile of CYP2C19 polymorphisms in population from Republic of Macedonia. Macedonian Pharmaceutic Bull. 2011; 57(Suppl): 346-348. 25. Jakovski K, Kapedanovska Netorovska A, Labacevski N, Dimovski AJ. Frequency of most common CYP3A5 polymorphisms in the healthy population of the Republic of Macedonia. Macedonian Pharmaceutic Bull. 2012; 58(1-2): 25-31. 26. Hildebrandt MA, Carrington DP, Thomae BA, Eckloff BW, Schaid DJ, Yee VC, et al. Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogenomics J. 2007; 7(2): 133-143. 27. Horsfall LJ, Zeitlyn D, Tarekegn A, Bekele E, Thomas MG, Bradman N, et al. Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann Hum Genet. 2011; 75(2): 236-246. 28. Polimanti R, Carboni C, Baesso I, Piacentini S, Iorio A, De Stefano GF, et al. Genetic variability of glutathione S-transferase enzymes in human populations: Functional inter-ethnic differences in detoxification systems. Gene. 2013; 512(1): 102-107. 29. Sterjev Z, Josifovski T, Panovski M, Sututkova L, Dimovski AJ. The SULT1A1 allele with low potential for estrogen inactivation is associated with reduced colorectal cancer risk in postmenopausal women. Balkan J Med Genet. 2005; 8(3-4): 43-48. 30. Bajro MH, Josifovski T, Panovski M, Jankulovski N, Nestorovska AK, Matevska N, et al. Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer. Cancer Genet. 2012; 205(4): 163-167. 31. Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res. 2008; 14(3): 817-825. 32. Wang H, Wang J, Zhao L, Liu X, Mi W. Methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia-evidence from an updated meta-analysis including 35 studies. BMC Med Genet. 2012; 4: 13-77. 33. Acuña M, Eaton L, Cifuentes L, Massardo D. Genetic variants in the enhancer region of the thymidylate synthase gene in the Chilean population. Br J Clin Pharmacol. 2006; 61(6): 778-782. 34. Alzahrani AM, Ragia G, Hanieh H, Manolopoulos VG. Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia. Biomed Res Int. 2013; 2013: 315980. doi: 10.1155/2013/3159980. 35. Matevska N, Josifovski T, Kapedanovska A, Sterjev Z, Serafimoska Z, Panovski M, et al. Methylenetetrahydrofolate reductase C677T polymorphism and risk of colorectal cancer in the Macedonian population. Balkan J Med Genet. 2008; 11(2):17-24. 36. Kapedanovska Nestorovska A, Sterjev Z, Serafimoska Z, Josifovski T, Petrusevska N, Suturkova L, et al. Thymidylate synthase enhancer region (TSER) 2R/3R polymorphisms as an independent risk factor for colorectal cancer in Macedonian population. Macedonian Pharmaceutic Bull. 2011; 57(Suppl): 348-349.



Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006